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EXPESSIVE DYSPHASIA POSSIBL Y RELATED TO FK506 IN 
TWO LIVER TRANSPLANT RECIPIENTS l 
The principal side effects of the new immunosuppressive 
drug FK506 have been low-grade nephrotoxicity, a mild diabe-
togenic effect. and annoying but relatively minor manifesta-
tions of neurotoxicity (1). The neurotoxic symptoms have 
included tremors, paresthesias, insomnia, headaches. increased 
visual sensitivity to light, nightmares, a sense of racing, and 
mood changes. Such complaints, which are similar to those 
caused by cyclosporine. have provided a much-needed means 
of dose adjustment (1). However. we report here 2 examples of 
reversible expressive dysphasia that may have been caused by 
FK506 since it was reversed by dose reduction. 
Both patients were treated from the time of liver transplan· 
tation with FK506. starting with an initial intravenous dose of 
0.15 mg/kg FK506 intraoperatively. Subsequent intravenous 
doses of 0.075 mg/kg were given every 12 hr, until the patients 
were able to take oral medications. At this time. 0.15 mg/kg 
FK506 was given orally every 12 hours. Methylprednisolone 
was started at 200 mg on day 1 and reduced by 40 mg steps/ 
day to 20 mg on day 6. 
A 43-year-old man with end-stage postnecrotic cirrhosis 
(liver weight 1400 g) secondary to hepatitis B did not have 
disabling encephalopathy preoperatively. He had an uncompli-
cated orthotopic liver transplantation, with a 3000 ml blood 
loss. He was discharged from the ICU after 3 days. On day 12, 
he was noted to have slurring of speech. He complained of 
numbness and tingling in his feet and also that his head was 
"racing." There was no arterial hypertension, nor any elevation 
of BUN or creatinine. Serum electrolytes were never abnormal, 
intraoperatively or later. The neurologic examination revealed 
an expressive dysphasia with slight tremors of the extremities. 
Fundoscopic findings, magnetic resonance imaging of the brain, 
and the spinal fluid were normal. A cerebral CT scan showed 
mild cortical atrophy, a finding that had been noted in the 
preoperative CT scan. An EEG showed generalized slowing. 
The neurologic symptoms gradually resolved after an FK506 
dose reduction. Despite a minor rejection episode, he improved 
steadily, and by the time of discharge, 25 days postoperatively, 
the speech defect was barely perceptible. He is neurologically 
normal 4 months postoperatively on FK506 doses of 0.09 mg/ 
kg/day (less than one-third of early postoperative oral dose) 
and 10 mg/day prednisone. 
A 38-year-old woman with chronic HBV hepatitis and grade 
III encephalopathy had an uncomplicated urgent liver trans-
plantation. Preoperatively, she was agitated and disoriented. 
Later, she became drowsy, disoriented, and bradykinetic. 1m· 
munosuppression was as in case 1. Postoperatively, she required 
1 This work was supported by Research Grants from the Veterans 
Administration and Project Grant DK 29961 from the National Insti-
tutes of Health. Bethesda, MD. 
prolonged ventilatory support and developed nonoliguric renal 
insufficiency-the serum creatinine rising from normal preop-
eratively to a peak of 5.3 mg/ dL The intravenous dose of FK506 
was decreased to .035 mg/kgjb.i.d. When the endotracheal tube 
was removed on day 6, she was noted to have an expressive 
speech deficit. Talking required a severe effort and there were 
occasional paraphasias. Her comprehension appeared to be 
normal, and repetitive speech was easier than spontaneous 
expression. A small subcortical left hemispheric stroke was 
suspected. However, a CT brain scan on days 6 and 12, carotid 
doppler examination, and echocardiogram (to rule out valve 
vegetations as an embolic source) were normaL The cerebro-
spinal fluid was normal. Her subsequent course was stormy and 
included Pseudomonas pneumonia, abdominal reoperation to 
remove a subhepatic hematoma, acute renal failure requiring 7 
hemodialyses, tracheostomy, and CMV gastritis. The FK506 
doses were intermittently stopped during this time and even-
tually resumed with oral doses of .07 mg/kg/day (about a 
quarter of the usual dose). 
When her tracheostomy was capped on day 41, she was noted 
still to have slurring of speech. Magnetic resonance imaging on 
the 41st postoperative day showed areas of demyelinization in 
the pons (Fig. 1). The oral dose of .07 mg/kg FK506 per day 
was maintained. The expressive dysphasia slowly improved and 
she was discharged on the 56th postoperative day. Her speech 
abnormalities completely resolved by postoperative day 90. She 
has never had a rejection. Maintenance immunosuppression 5 
months postoperatively is with 0.06 mg/kg/day FK506 without 
steroids, which were stopped on the 16th postoperative day. 
Pathologic changes can frequently be found in the central 
nervous system of patients who die of chronic liver disease (2). 
The same abnormalities have been seen at autopsy after un-
successful transplantation under azathioprine and cyclosporine 
regimens (3,4). In order of frequency, these include Alzheimer 
type II changes in the glial tissue, depletion of the myelin in 
the pons (central pontine myelinolysis) or elsewhere in the 
brain stem or higher brain (extrapontine myelinolysis), and 
cortical atrophy. 
The neurologic syndromes have included prolonged obtund-
ation or disorientation, flaccid quadriplegia, pseudobulbar 
palsy, expressive dysphasia, akinetic mutism, neuroopthomo-
logic abnormalities, convulsions, and coma (3, 4). Similar Alz-
heimer and myelinolytic changes can be produced reliably in 
rats by surgical portacaval anastomosis, even though the ani-
mals may appear well clinically (5). Thus, vulnerability from 
underlying neuropathologic abnormalities of the central nerv-
ous system during the stressful period of liver transplantation 
is the background against which the role of any single factor, 
including drugs, must be evaluated in the event of a neurologic 
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FIGURE 1. NMR in patient 2 on the 41st postoperative day. Note 
the bright pontine lesion (arrow). which was thought to be an area of 
demyelinization. 
complication. The possible aggravating role of overly aggressive 
electrolyte correction has been emphasized by many workers, 
as summarized by Wszolek et al. (6) . 
Nevenheless, the possible neurologic complications of 
chRMS~including the reversible pontine demyelinization seen 
in case 2 by kMo~resemble some of those ascribed to cyclo-
sporine (7). In the cyclosporine repons. the neurotoxicity was 
associated casually with low cholesterol (8), hypomagnesemia 
(7), and aluminum overload (9). These latter findings are 
probably epiphenomena even if they are contributory to the 
pathogenesis. 
A more fundamental explanation may be advanced for the 
neurotoxicity of these drugs.' Although they are distinct, the 
binding sites of both cyclosporine and FK506 contain cis-trans 
peptidyl prolyl isomerase (10. 11). Inhibition of this enzyme 
could explain many metabolic effects of both drugs, including 
cholesterol regulation' and reduction of magnesium (12). It is 
also doubtful that hypocholesterolemia has a direct casual role 
in the neurotoxicity (13). Although hypocholesterolemia is 
uniformly produced by FK506, the 2 examples of major neuro-
logic complications herein reponed were the only ones with a 
probable FK506 etiology seen in recipients of 180 livers, 55 
kidneys, and 18 heans, lungs, and hean-Iungs treated primarily 
with this drug in the last 13 months. Seizures have occurred in 
our liver transplant recipients with a lower frequency than in 
the past. Although we are making a systematic search tQ 
establish a specific etiology in each case, this has been difficUlt 
because of the multifactorial nature of this complication in 
liver recipients. Seizures have not been seen in the recipientg 
of extrahepatic organs. 
An imponant possibility is that there is a direct inhibitory 
effect of drugs like cyclosporine and FK506 on cis-trans pepti-
dyl prolyl isomerase receptors in the central nervous system 
as has been suggested elsewhere. J Focal CNS targets made mo~ 
susceptible by previous liver disease or any of the contributory 
factors mentioned earlier could be selectively affected by Over-
dosage. The first intravenous dose of 0.15 mg/kg FK506 used 
in our early experience has been reduced since to 0.075 mg!kg 
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ADJUVANT RADIOCHEMOTHERAPY FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION FOR BILE 
DUCT CANCER 
Primary cancer of the bile ducts is an uncommon disease 
that accounts for 4500 new cancer patients annually in the 
United States (1). Although disease extension is generally 
locoregionally delimited at the time of surgery (2, 3), curative 
resection is possible in only 10-20% of cases (4). The pattern 
of loco regional recurrence in a significant percentage of patients 
(2,5,6) has led to evaluation of primary and adjuvant regional 
radiation therapy with suggestive but inconclusive results (6-
8). Likewise, there are preliminary reports of combined-modal-
ity radiochemotherapy (9, 10), These studies are based on the 
low-but-definite response rates in patients with bile duct cancer 
treated with 5-fluorouracil (5-FU)* (11) and the potential for 
5-FU radiosensitization (12). 
Experience with orthotopic liver transplantation for bile duct 
cancer is limited, but the results are not impressive (13-18). 
The disease usually has recurred within the first year following 
surgery in patients who have survived the early postoperative 
period. Regional lymph nodes and the allograft are the most 
common sites of initial recurrence. In light of these disappoint-
ing results, three patients found to have bile duct cancer at the 
time of OL T for preoperative diagnoses of hepatocellular car-
cinoma (2) or recurrent bile duct adenoma (1) were treated 
with postoperative regional radiation and 5-FU radiosensitiza-
tion. Our experience with these patients (described here) forms 
the basis of the protocol currently used at Baylor University 
Medical Center for patients undergoing OL T for unresectable 
nonmetastatic bile duct cancer. 
The three patients had no evidence of gross extrahepatic, 
extranodal metastatic disease; had one or more high-risk factors 
for regional recurrence-e.g., hilar soft tissue invasion, peri-
neural involvement, or metastatic disease to liver and/or re-
gionallymph nodes; and had given informed consent. 
Within five to nine weeks after OL T, radiation therapy was 
initiated to the targeted region of the porta hepatis and regional 
lymph nodes (including the celiac and pancreaticoduodenal 
nodal chains). Using 24 MeV x-rays via multiple-field tech-
niques, 55.8 Gy was delivered in 31 fractions over 44 days. 
Concurrent 5-FU was administered by 96-hr intravenous infu-
sion at 8 dose of 450 mg/m2/24 hr during weeks 1 and 4 of 
radiation. Patients received the usual postoperative immuno-
suppressive regimen, consisting of cyclosporine and methyl-
prednisolone or prednisolone. 
Case 1. A 39-year-old man developed diarrhea, nausea, vom-
iting, jaundice, and pruritus in April 1987. Serology indicated 
previous infection with hepatitis A, and a liver biopsy was 
nondiagnostic. Enterohepatic retrograde cholangiopancreatog-
raphy (ERCP) was compatible with a diagnosis of sclerosing 
cholangitis. He was started on prednisone with initial clinical 
* Abbreviations: ERCP, enterohepatic retrograde cholangiopancrea-
tography; 5·FU, 5 fluorouracil; MRM, modified radical mastectomy. 
and laboratory value improvement. Attempts to taper the ste-
roids resulted in clinical deterioration, and the maintenance 
dose was increased to 60 mg daily in February 1988. Two 
months later, the patient developed fever, chills, and cough. A 
chest roentgenogram revealed a cavitary lesion. At bronchos-
copy, a Nocardia infection was diagnosed, and he was started 
on trimethoprim-sulfamethoxazole with symptomatic improve-
ment. Prednisone was tapered to 20 mg daily, and the patient 
was referred to this institution to be evaluated for possible liver 
transplantation. Magnetic resonance imaging revealed a large 
central liver defect, and a CT· guided biopsy taken on 6/13/88 
was interpreted to be consistent with poorly differentiated 
carcinoma, most likely hepatocellular carcinoma. Physical ex-
amination showed jaundice with moderate muscle wasting. 
Neither the liver nor spleen was palpable. The serum alpha-
fetoprotein level was 1.8 ng/ml (normal <18 ng/m/) and liver 
function studies showed total bilirubin 21 mg/dl, alkaline phos-
phatase 921, SGOT 207, SGPT 288, and LDH 291 U/L. 
The patient was initially placed on our neoadjuvant chemo-
therapy-OLT protocol for hepatocellular carcinoma (19) and 
received a 28 mg/m2-cumulative dose of doxorubicin pre- and 
intraoperatively. After OLTon 6/24/88, histopathological ex-
amination revealed a cholangiocarcinoma (13xlO.5X11.5 cm) 
centered at the confluence of the left and right hepatic ducts, 
scattered intraparenchymal lesions, focal invasion of connec-
tive tissue at the hilum, perineural invasion, and metastatic 
disease in one hilar lymph node. Radiation therapy and 5-FU 
were initiated six weeks postoperatively. Therapy was well 
tolerated without evidence of gastrointestinal or hematologic 
toxicity. He continues to do well 21 months posttransplantation 
without evidence of recurrent neoplasm by clinical, laboratory, 
or imaging criteria. 
Case 2. This 35-year-old woman had right upper quadrant 
pain of three months' duration. Abdominal CT scan showed a 
mass (8 cm) in the central portion of the liver. On 7/1/88, 
tissue from a CT-directed liver biopsy was interpreted as con-
sistent with hepatocellular carcinoma. MRI at Baylor Univer-
sity Medical Center confirmed the presence of a solitary mass 
(8x8X5 cm) at the juncture of the right and left portal veins. 
The patient had no history of liver disease, but family history 
disclosed that a maternal aunt had died at age 70 of a malignant 
liver tumor. Physical examination showed the liver edge pal-
pable 4 em below the right costal margin and extending into 
the epigastrium. The spleen was not palpable. Serum AFP was 
3.1 ng/ml; HB.Ag and HBcAb were negative; and liver function 
tests showed a normal bilirubin, minimally elevated transami-
nases, and alkaline phosphatase 230 U/L (normal <115 U/L). 
The patient initially was entered on our neoadjuvant chemo-
therapy-OL T protocol, receiving 38 mg/m2 cumulative pre-
and perioperative doxorubicin (19). After OLT on 7/28/88, 
histopathological examination showed a cholangiocarcinoma 
